Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Pariser

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Journal of the American Academy of Dermatology|January 30, 2013
OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasisAlexa B Kimball, David Pariser, Paul S Yamauchi, et al.
The New England Journal of Medicine|January 18, 2008
Etanercept treatment for children and adolescents with plaque psoriasisAmy S Paller, Elaine C Siegfried, Richard G Langley, et al.
Journal of Drugs in Dermatology : JDD|March 5, 2015
Evolving perspectives on the etiology and pathogenesis of acne vulgarisLawrence F Eichenfield, James Q Del Rosso, Anthony J Mancini, et al.
The Journal of Allergy and Clinical Immunology. in Practice|October 4, 2017
Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging TherapiesMark Boguniewicz, Andrew F Alexis, Lisa A Beck, et al.
Journal of Drugs in Dermatology : JDD|February 23, 2019
Systemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in PracticeMark Lebwohl, Andrew F. Alexis, Lisa A. Beck, et al.
The British Journal of Dermatology|March 12, 2024
Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trialsChristos C Zouboulis, Thierry Passeron, David Pariser, et al.
Journal of the American Academy of Dermatology|September 30, 2014
OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year resultsAlexa B Kimball, Kenneth J Rothman, Gregory Kricorian, et al.
Journal of Drugs in Dermatology : JDD|August 4, 2010
Tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for treatment of acne vulgaris: morning/morning regimen is as effective and safe as morning/evening regimenDavid Pariser, Alicia Bucko, Richard Fried, et al.
Cutis|August 2, 2003
Efficacy and safety of a new triple-combination agent for the treatment of facial melasmaSusan C Taylor, Helen Torok, Terry Jones, et al.
JAMA Dermatology|November 7, 2019
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical TrialEric L Simpson, Amy S Paller, Elaine C Siegfried, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Journal of the American Academy of Dermatology|January 30, 2013
OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasisAlexa B Kimball, David Pariser, Paul S Yamauchi, et al.
The New England Journal of Medicine|January 18, 2008
Etanercept treatment for children and adolescents with plaque psoriasisAmy S Paller, Elaine C Siegfried, Richard G Langley, et al.
Journal of Drugs in Dermatology : JDD|March 5, 2015
Evolving perspectives on the etiology and pathogenesis of acne vulgarisLawrence F Eichenfield, James Q Del Rosso, Anthony J Mancini, et al.
The Journal of Allergy and Clinical Immunology. in Practice|October 4, 2017
Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging TherapiesMark Boguniewicz, Andrew F Alexis, Lisa A Beck, et al.
Journal of Drugs in Dermatology : JDD|February 23, 2019
Systemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in PracticeMark Lebwohl, Andrew F. Alexis, Lisa A. Beck, et al.
The British Journal of Dermatology|March 12, 2024
Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trialsChristos C Zouboulis, Thierry Passeron, David Pariser, et al.
Journal of the American Academy of Dermatology|September 30, 2014
OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year resultsAlexa B Kimball, Kenneth J Rothman, Gregory Kricorian, et al.
Journal of Drugs in Dermatology : JDD|August 4, 2010
Tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for treatment of acne vulgaris: morning/morning regimen is as effective and safe as morning/evening regimenDavid Pariser, Alicia Bucko, Richard Fried, et al.
Cutis|August 2, 2003
Efficacy and safety of a new triple-combination agent for the treatment of facial melasmaSusan C Taylor, Helen Torok, Terry Jones, et al.
JAMA Dermatology|November 7, 2019
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical TrialEric L Simpson, Amy S Paller, Elaine C Siegfried, et al.
Pageof 7